相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Christopher Nevala-Plagemann et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis
Tobias Forster et al.
ONCOLOGY (2020)
MicroRNA-628-5p inhibits invasion and migration of human pancreatic ductal adenocarcinoma via suppression of the AKT/NF-kappa B pathway
Lin Zhou et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer
Austin R. Dosch et al.
MOLECULAR CANCER RESEARCH (2020)
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors
Gregory L. Beatty et al.
ONCOLOGIST (2019)
Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway
Lehe Yang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
Thorvardur R. Halfdanarson et al.
ONCOLOGIST (2019)
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma
Martin R. Jones et al.
CLINICAL CANCER RESEARCH (2019)
Dihydrosanguinarine suppresses pancreatic cancer cells via regulation of mut-p53/WT-p53 and the Ras/Raf/Mek/Erk pathway
Wu Si-zhi et al.
PHYTOMEDICINE (2019)
Wnt/β-Catenin Signaling: The Culprit in Pancreatic Carcinogenesis and Therapeutic Resistance
Monish Ram Makena et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition
Teena Dhir et al.
MOLECULAR CANCER RESEARCH (2019)
126OOlaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial
D-Y Oh et al.
ANNALS OF ONCOLOGY (2019)
Quercetin facilitates cell death and chemosensitivity through RAGE/PI3K/AKT/mTOR axis in human pancreatic cancer cells
Chieh-Yu Lan et al.
JOURNAL OF FOOD AND DRUG ANALYSIS (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
R. Tuli et al.
EBIOMEDICINE (2019)
Indirubin 3′-Oxime Inhibits Migration, Invasion, and Metastasis In Vivo in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways
Yoshimi Ichimaru et al.
TRANSLATIONAL ONCOLOGY (2019)
Identification of targetable BRAFΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma
Kazimierz O. Wrzeszczynski et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2019)
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2018)
Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer
Yefeng Yin et al.
CANCER LETTERS (2018)
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
Nithya Krishnamurthy et al.
CANCER TREATMENT REVIEWS (2018)
Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
Zishuo I. Hu et al.
CLINICAL CANCER RESEARCH (2018)
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
Maeve A. Lowery et al.
EUROPEAN JOURNAL OF CANCER (2018)
Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas
Renato M. Lupinacci et al.
GASTROENTEROLOGY (2018)
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
Reham Abdel-Wahab et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer
Dana B. Cardin et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
Hongmei Jiang et al.
MOLECULAR CANCER THERAPEUTICS (2018)
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer
N. Stojanovic et al.
ONCOGENE (2017)
Hypermutation In Pancreatic Cancer
Jeremy L. Humphris et al.
GASTROENTEROLOGY (2017)
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
Marianne Sinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma
Aatur D. Singhi et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
Gary Middleton et al.
LANCET ONCOLOGY (2017)
Evaluation of insulin-like growth factor (IGF-1) and retinol binding protein (RBP-4) levels in patients with newly diagnosed pancreatic adenocarcinoma (PDAC)
Barbara Wlodarczyk et al.
PANCREATOLOGY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial
Fayth L. Miles et al.
NUTRIENTS (2017)
Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells
Katrina M. Burchett et al.
ONCOTARGET (2017)
Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study
Livia Archibugi et al.
SCIENTIFIC REPORTS (2017)
Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma
Richard Tuli et al.
JCO PRECISION ONCOLOGY (2017)
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
B. Schultheis et al.
ANNALS OF ONCOLOGY (2017)
Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer An Eastern Cooperative Oncology Group Study
Barbara Burtness et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy
Ekaterina Pak et al.
DEVELOPMENTAL CELL (2016)
Statin Use and Its Impact on Survival in Pancreatic Cancer Patients
Hee Seung Lee et al.
MEDICINE (2016)
Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer
Emily Chan et al.
RADIOTHERAPY AND ONCOLOGY (2016)
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial
Khurum Khan et al.
ONCOTARGET (2016)
Protein kinase C beta II suppresses colorectal cancer by regulating IGF-1 mediated cell survival
Catriona M. Dowling et al.
ONCOTARGET (2016)
Pancreatic cancer biology and genetics from an evolutionary perspective
Alvin Makohon-Moore et al.
NATURE REVIEWS CANCER (2016)
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic canceraEuro
B. H. O'Neil et al.
ANNALS OF ONCOLOGY (2015)
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
S. Kordes et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer
Zheng Wu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies
Shanliang Zhong et al.
CANCER TREATMENT REVIEWS (2015)
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
A. H. Ko et al.
CLINICAL CANCER RESEARCH (2015)
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Spring Holter et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma
Anupam Mitra et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
PI3King the Lock: Targeting the PI3K/Akt/mTOR Pathway as a Novel Therapeutic Strategy in Neuroblastoma
David King et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2015)
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the THERAPY phase 1-2 trial
Eric Assenat et al.
ONCOTARGET (2015)
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Philippe L. Bedard et al.
CLINICAL CANCER RESEARCH (2015)
Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer
Bo Tang et al.
SCIENTIFIC REPORTS (2015)
A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.
Robert R. McWilliams et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Dual Blockade of Epidermal Growth Factor Receptor and Insulin-Like Growth Factor Receptor-1 Signaling in Metastatic Pancreatic Cancer Phase Ib and Randomized Phase II Trial of Gemcitabine, Erlotinib, and Cixutumumab Versus Gemcitabine Plus Erlotinib (SWOG S0727)
Philip A. Philip et al.
CANCER (2014)
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)
T. Dragovich et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Susann Weissmueller et al.
CELL (2014)
Mechanism and regulation of incisions during DNA interstrand cross-link repair
Jieqiong Zhang et al.
DNA REPAIR (2014)
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study
D. J. Watkins et al.
EUROPEAN JOURNAL OF CANCER (2014)
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta et al.
INVESTIGATIONAL NEW DRUGS (2014)
Evidence for the Importance of Personalized Molecular Profiling in Pancreatic Cancer
Loukia N. Lili et al.
PANCREAS (2014)
Telomerase Inhibitor Imetelstat (GRN163L) Limits the Lifespan of Human Pancreatic Cancer Cells
Katrina M. Burchett et al.
PLOS ONE (2014)
Signaling mechanisms of the epithelial-mesenchymal transition
David M. Gonzalez et al.
SCIENCE SIGNALING (2014)
Precursor Lesions for Sporadic Pancreatic Cancer: PanIN, IPMN, and MCN
M. Distler et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer
Dana B. Cardin et al.
CANCER MEDICINE (2014)
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
S. Boeck et al.
BRITISH JOURNAL OF CANCER (2013)
Targeting microRNAs in Pancreatic Cancer: Microplayers in the Big Game
Sheema Khan et al.
CANCER RESEARCH (2013)
Breast Cancer Stem Cells: A Novel Therapeutic Target
Sudeshna Gangopadhyay et al.
CLINICAL BREAST CANCER (2013)
Poly(ADP-ribosylation) and Neoplastic Transformation: Effect of PARP Inhibitors
Francesca Dona et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2013)
Clinical Value of Circulating Lipocalins and Insulin-Like Growth Factor Axis in Pancreatic Cancer Diagnosis
Hala O. El-Mesallamy et al.
PANCREAS (2013)
Human Pancreatic Cancer Contains a Side Population Expressing Cancer Stem Cell-Associated and Prognostic Genes
Anke Van den Broeck et al.
PLOS ONE (2013)
Notch signaling in pancreatic cancer: oncogene or tumor suppressor?
Jacqueline L. Avila et al.
TRENDS IN MOLECULAR MEDICINE (2013)
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
R. Pili et al.
BRITISH JOURNAL OF CANCER (2012)
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
J. Harder et al.
BRITISH JOURNAL OF CANCER (2012)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)
Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
Wan-Ching Yen et al.
CLINICAL CANCER RESEARCH (2012)
Targeting EGFR in Pancreatic Cancer Treatment
T. Troiani et al.
CURRENT DRUG TARGETS (2012)
Genistein Inhibits Cell Growth and Induces Apoptosis Through Up-regulation of miR-34a in Pancreatic Cancer Cells
Jun Xia et al.
CURRENT DRUG TARGETS (2012)
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
Hedy Lee Kindler et al.
INVESTIGATIONAL NEW DRUGS (2012)
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
Gyoergy Bodoky et al.
INVESTIGATIONAL NEW DRUGS (2012)
Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition
Kavitha Gowrishankar et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Genetic susceptibility to pancreatic cancer
Alison P. Klein
MOLECULAR CARCINOGENESIS (2012)
SMAD4 Genetic Alterations Predict a Worse Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
Puneet Singh et al.
PANCREAS (2012)
Sonic Hedgehog in pancreatic cancer: From bench to bedside, then back to the bench
David E. Rosow et al.
SURGERY (2012)
Mouse models of pancreatic cancer
Marta Herreros-Villanueva et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer A Phase II Study
Howard Safran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth
Nagathihalli S. Nagaraj et al.
CLINICAL CANCER RESEARCH (2011)
Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer.
M. M. Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L. Kindler et al.
LANCET ONCOLOGY (2011)
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Maria M. Mihaylova et al.
NATURE CELL BIOLOGY (2011)
Characterization of the DNA binding specificity of Shelterin complexes
Kyung H. Choi et al.
NUCLEIC ACIDS RESEARCH (2011)
An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions
Maeve A. Lowery et al.
ONCOLOGIST (2011)
Human Tumour Immune Evasion via TGF-β Blocks NK Cell Activation but Not Survival Allowing Therapeutic Restoration of Anti-Tumour Activity
Erica B. Wilson et al.
PLOS ONE (2011)
Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Daniel F. Egan et al.
SCIENCE (2011)
Telomerase: An RNP Enzyme Synthesizes DNA
Elizabeth H. Blackburn et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2011)
RAF protein-serine/threonine kinases: Structure and regulation
Robert Roskoski
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
Milind M. Javle et al.
BMC CANCER (2010)
Molecular Predictors of Outcome in a Phase 3 Study of Gemcitabine and Erlotinib Therapy in Patients With Advanced Pancreatic Cancer National Cancer Institute of Canada Clinical Trials Group Study PA 3
Gilda da Cunha Santos et al.
CANCER (2010)
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
Andrew H. Ko et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 Molar Ratio and Risk of Pancreatic Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Jason B. Douglas et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics
Vanessa Rausch et al.
CANCER RESEARCH (2010)
In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer
Masahiro Komoto et al.
CANCER SCIENCE (2010)
Pancreatic Duct Glands Are Distinct Ductal Compartments That React to Chronic Injury and Mediate Shh-Induced Metaplasia
Oliver Strobel et al.
GASTROENTEROLOGY (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mismatch repair deficient colorectal cancer in the era of personalized treatment
Madeleine Hewish et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
Ruth Halaban et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Dominico Vigil et al.
NATURE REVIEWS CANCER (2010)
Linking the Cellular Functions of BRCA Genes to Cancer Pathogenesis and Treatment
Ashok R. Venkitaraman
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway
Zhiwei Wang et al.
CANCER RESEARCH (2009)
Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer
Michael E. Mullendore et al.
CLINICAL CANCER RESEARCH (2009)
Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer
Joanna M. Brell et al.
ONCOLOGY (2009)
How Shelterin Protects Mammalian Telomeres
Wilhelm Palm et al.
ANNUAL REVIEW OF GENETICS (2008)
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: A phase II study of the Hellenic Cooperative Oncology Group with biomarker evaluation
George Fountzilas et al.
CANCER INVESTIGATION (2008)
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
Jennifer M. Bailey et al.
CLINICAL CANCER RESEARCH (2008)
TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells
Rossana Trotta et al.
JOURNAL OF IMMUNOLOGY (2008)
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer:: an open-label randomised phase II study
Jean-Philippe Spano et al.
LANCET (2008)
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells
Elisa Sala et al.
MOLECULAR CANCER RESEARCH (2008)
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
[Anonymous]
LANCET ONCOLOGY (2008)
Rapid regulation of telomere length is mediated by poly(ADP-ribose) polymerase-1
Sascha Beneke et al.
NUCLEIC ACIDS RESEARCH (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Insulin and insulin-like growth factor signalling in neoplasia
Michael Pollak
NATURE REVIEWS CANCER (2008)
Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression
Stephanie K. Bunt et al.
CANCER RESEARCH (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors:: A clinical and translational study
Pamela Muenster et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers
Georg Feldmann et al.
CANCER RESEARCH (2007)
Identification of pancreatic cancer stem cells
Chenwei Li et al.
CANCER RESEARCH (2007)
Hedgehog/Ras interactions regulate early stages of pancreatic cancer
Marina Pasca di Magliano et al.
GENES & DEVELOPMENT (2006)
Poly(ADP-ribose):: novel functions for an old molecule
Valerie Schreiber et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study
D. A. Richards et al.
ANNALS OF ONCOLOGY (2006)
Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells
Todd W. Bauer et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Genetics and biology of pancreatic ductal adenocarcinoma
Aram F. Hezel et al.
GENES & DEVELOPMENT (2006)
The epithelial-mesenchymal transition: new insights in signaling, development, and disease
JM Lee et al.
JOURNAL OF CELL BIOLOGY (2006)
Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX (R) vaccine in advanced-stage non-small-cell lung cancer
J Nemunaitis et al.
CANCER GENE THERAPY (2006)
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
DA Thomas et al.
CANCER CELL (2005)
Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer
HL Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition
BS Herbert et al.
ONCOGENE (2005)
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics
H Seimiya et al.
CANCER CELL (2005)
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
GA Repasky et al.
TRENDS IN CELL BIOLOGY (2004)
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors
LR Pauer et al.
CANCER INVESTIGATION (2004)
The Akt pathway: Molecular targets for anti-cancer drug development
CS Mitsiades et al.
CURRENT CANCER DRUG TARGETS (2004)
Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine
P Boya et al.
ONCOGENE (2003)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression
T Sánchez-Elsner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma
H Safran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
TGFβ signaling in growth control, cancer, and heritable disorders
J Massagué et al.
CELL (2000)
分享论文
